GenixPharmaceucticals Corporation Market Cap ($664.33K)
Market Cap & Net Worth: GenixPharmaceucticals Corporation (GENX)
GenixPharmaceucticals Corporation market cap. GenixPharmaceucticals Corporation (V:GENX) has a market capitalization of $664.33K (CA$918.36K) as of November 1, 2026. Listed on the V stock exchange, this Canada-based company holds position #30920 globally and #1618 in its home market, demonstrating a -25.00% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying GenixPharmaceucticals Corporation's stock price CA$0.02 by its total outstanding shares 61224131 (61.22 Million). Also see how efficiently does GenixPharmaceucticals Corporation generate cash for how efficiently the company converts equity into cash flow.
GenixPharmaceucticals Corporation Market Cap History (2015–2026)
GenixPharmaceucticals Corporation market cap history from 2015 to 2026. Data shows change from $2.21 Million to $664.33K (-8.53% CAGR). Check GenixPharmaceucticals Corporation share price for real-time trading data and today's change.
GenixPharmaceucticals Corporation Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how GenixPharmaceucticals Corporation's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of GenixPharmaceucticals Corporation to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
601.30x
GenixPharmaceucticals Corporation's market cap is 601.30 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.55 Million | $924.70K | -$129.05K | 1.68x | N/A |
| 2017 | $4.43 Million | $1.01 Million | -$243.21K | 4.38x | N/A |
| 2018 | $2.44 Million | $419.96K | $134.07K | 5.80x | 18.17x |
| 2019 | $3.10 Million | $137.40K | -$164.70K | 22.56x | N/A |
| 2023 | $885.77K | $12.35K | -$4.40 Million | 71.74x | N/A |
| 2024 | $2.44 Million | $4.05K | -$73.20K | 601.30x | N/A |
Competitor Companies of GENX by Market Capitalization
Companies near GenixPharmaceucticals Corporation in the global market cap rankings as of November 1, 2026. Also see GenixPharmaceucticals Corporation assets under control for a full breakdown of the balance sheet.
Key companies related to GenixPharmaceucticals Corporation by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #535 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #593 globally with a market cap of $45.23 Billion USD ( CN¥309.13 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #535 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.62 |
| #593 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.23 Billion | CN¥48.46 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.30 |
Market Capitalization of GenixPharmaceucticals Corporation (2015–2026)
Market capitalization of GenixPharmaceucticals Corporation from 2015 to today. Between 2015 and today, GenixPharmaceucticals Corporation's market cap moved from $2.21 Million to $ 664.33K, with a yearly change of -8.53%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CA$664.33K | -50.00% |
| 2025 | CA$1.33 Million | -45.45% |
| 2024 | CA$2.44 Million | +175.00% |
| 2023 | CA$885.77K | -73.33% |
| 2022 | CA$3.32 Million | -34.78% |
| 2021 | CA$5.09 Million | -32.35% |
| 2020 | CA$7.53 Million | +142.86% |
| 2019 | CA$3.10 Million | +27.27% |
| 2018 | CA$2.44 Million | -45.00% |
| 2017 | CA$4.43 Million | +185.71% |
| 2016 | CA$1.55 Million | -30.00% |
| 2015 | CA$2.21 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of GenixPharmaceucticals Corporation was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $664.33K USD |
| MoneyControl | $664.33K USD |
| MarketWatch | $664.33K USD |
| marketcap.company | $664.33K USD |
| Reuters | $664.33K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About GenixPharmaceucticals Corporation
Genix Pharmaceuticals Corporation formulates, manufactures, licenses, and markets life sciences related products with a focus on nutraceuticals and pharmaceuticals in Canada. The company offers generic ophthalmic prescription products, ophthalmic nutraceutical formulations, and prescription generic drugs; ophthalmic OTC products; and eye ointments and drops. It also provides Flu-X, an anti-viral,… Read more